AKBA AKEBIA THREAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AKEBIA THREAPEUTICS INC reported revenue of $49.1M (down 21.4% from a year earlier), net income of −$8.91M and diluted EPS of −$0.03; over the last four quarters revenue was $219M and net income −$29.6M; for the fiscal year ended December 2025 revenue was $236M, up 47.5% on the year before.

AKBA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $236M, gross profit n/a, operating income $23.5M, net income −$5.30M (margin -2.2%), EPS −$0.02
• Fiscal year ended Dec 2024: revenue $160M, gross profit n/a, operating income −$50.5M, net income −$69.4M (margin -43.3%), EPS −$0.33
• Fiscal year ended Dec 2023: revenue $195M, gross profit n/a, operating income −$46.3M, net income −$51.9M (margin -26.7%), EPS −$0.28
• Fiscal year ended Dec 2022: revenue $292M, gross profit n/a, operating income −$80.8M, net income −$94.2M (margin -32.2%), EPS −$0.52
• Fiscal year ended Dec 2021: revenue $212M, gross profit n/a, operating income −$265M, net income −$282M (margin -133.2%), EPS −$1.70

AKBA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $49.1M (down 21.4% year over year), net income −$8.91M, EPS −$0.03
• Quarter ended Mar 31, 2026: revenue $53.5M (down 6.6% year over year), net income −$9.05M, EPS −$0.03
• Quarter ended Dec 31, 2025 (from the annual report): revenue $57.6M (up 23.9% year over year), net income −$12.2M, EPS −$0.05
• Quarter ended Sep 30, 2025: revenue $58.8M (up 57.0% year over year), net income $540K, EPS $0.00
• Quarter ended Jun 30, 2025: revenue $62.5M (up 43.1% year over year), net income $247K, EPS $0.00
• Quarter ended Mar 31, 2025: revenue $57.3M (up 75.8% year over year), net income $6.11M, EPS $0.03
• Quarter ended Dec 31, 2024 (from the annual report): revenue $46.5M (down 17.3% year over year), net income −$22.8M, EPS −$0.10
• Quarter ended Sep 30, 2024: revenue $37.4M (down 11.0% year over year), net income −$20.0M, EPS −$0.10
• Quarter ended Jun 30, 2024: revenue $43.6M (down 22.6% year over year), net income −$8.58M, EPS −$0.04
• Quarter ended Mar 31, 2024: revenue $32.6M (down 18.5% year over year), net income −$18.0M, EPS −$0.09
• Quarter ended Dec 31, 2023 (from the annual report): revenue $56.2M (up 0.9% year over year), net income $637K, EPS $0.01
• Quarter ended Sep 30, 2023: revenue $42.0M (down 13.7% year over year), net income −$14.5M, EPS −$0.08
• Quarter ended Jun 30, 2023: revenue $56.4M (down 55.4% year over year), net income −$11.2M, EPS −$0.06
• Quarter ended Mar 31, 2023: revenue $40.0M (down 35.2% year over year), net income −$26.9M, EPS −$0.15
• Quarter ended Dec 31, 2022 (from the annual report): revenue $55.7M (down 3.4% year over year), net income −$6.04M, EPS −$0.03
• Quarter ended Sep 30, 2022: revenue $48.7M (down 0.1% year over year), net income −$54.1M, EPS −$0.29
• Quarter ended Jun 30, 2022: revenue $126M (up 138.8% year over year), net income $29.4M, EPS $0.15
• Quarter ended Mar 31, 2022: revenue $61.7M (up 18.0% year over year), net income −$63.5M, EPS −$0.35
• Quarter ended Dec 31, 2021 (from the annual report): revenue $57.7M, net income −$69.8M, EPS −$0.40
• Quarter ended Sep 30, 2021: revenue $48.8M, net income −$59.5M, EPS −$0.34

AKBA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $68.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$40.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$23.4M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$73.2M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$253M, share buybacks n/a

AKBA balance sheet

• Jun 30, 2026: cash $156M, total assets $350M, total liabilities $325M, shareholders' equity $25.0M, long-term debt $24.8M
• Mar 31, 2026: cash $163M, total assets $363M, total liabilities $335M, shareholders' equity $27.4M, long-term debt $36.4M
• Dec 31, 2025: cash $185M, total assets $377M, total liabilities $344M, shareholders' equity $32.6M, long-term debt $48.3M
• Sep 30, 2025: cash $166M, total assets $364M, total liabilities $323M, shareholders' equity $41.6M, long-term debt $47.6M
• Jun 30, 2025: cash $137M, total assets $346M, total liabilities $316M, shareholders' equity $29.2M, long-term debt $47.1M
• Mar 31, 2025: cash $113M, total assets $310M, total liabilities $286M, shareholders' equity $24.6M, long-term debt $46.5M
• Dec 31, 2024: cash $51.9M, total assets $221M, total liabilities $270M, shareholders' equity −$49.2M, long-term debt $38.7M
• Sep 30, 2024: cash $34.0M, total assets $207M, total liabilities $258M, shareholders' equity −$50.4M, long-term debt $38.4M

What is AKBA's revenue?

AKEBIA THREAPEUTICS INC reported $219M of revenue over its last four quarters, through June 30, 2026.

Is AKBA profitable?

No. AKEBIA THREAPEUTICS INC lost $29.6M over the last four quarters.

What is AKBA's EPS?

Diluted earnings per share over the last four quarters were −$0.11; −$0.03 in the latest quarter.

AKBA ownership and insider trades · All stocks